^
Association details:
| Biomarker: | MET amplification + MET Exon 14 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1384P - Phase II study of cabozantinib in patients with MET-altered lung cancers
Published date:
10/16/2023
Excerpt:
In this single-arm phase 2 trial, patients (pts) with stage IV MET-altered lung cancers received cabozantinib 60 mg daily until progressive disease or intolerable toxicity….The ORR was 17% (4/24; 95% CI 6.8-35.8%; MET skipping mutation, n=3; concurrent MET skipping mutation and MET amplification, n=1) and the disease control rate was 71% (95% CI 50.8-85.1%; partial response, n=4; stable disease, n=13, one with MET D1228N).
Trial ID:
